Edition:
United Kingdom

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.24USD
19 Apr 2018
Change (% chg)

$0.01 (+0.81%)
Prev Close
$1.23
Open
$1.22
Day's High
$1.24
Day's Low
$1.20
Volume
14,136
Avg. Vol
51,067
52-wk High
$2.12
52-wk Low
$1.06

Latest Key Developments (Source: Significant Developments)

FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO'S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​.FDA CLEARS PLURISTEM’S EXPANDED ACCESS PROGRAM TO INITIATE TREATMENTS OF CRITICAL LIMB ISCHEMIA OUTSIDE OF ONGOING PHASE III STUDY.  Full Article

Pluristem enters agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Pluristem Therapeutics Inc :Pluristem enters into agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD.  Full Article

PLURISTEM PRICES PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE.PLURISTEM THERAPEUTICS INC - ‍PRICING OF PUBLIC OFFERING OF 9 MILLION SHARES ON TEL AVIV STOCK EXCHANGE AT PRICE OF $1.67 (NIS 5.90) PER SHARE​.  Full Article

Pluristem extends trial for treatment of insufficient hematopoietic recovery
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Pluristem Therapeutics Inc :Following approval of israel’s ministry of health, Pluristem extends its trial of plx-r18 to treat insufficient Hematopoietic recovery after bone marrow transplant and opens clinical centers in Israel.Pluristem therapeutics inc - ‍Israeli clinical sites will join an ongoing u.s. Phase I trial​.  Full Article

FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Pluristem Therapeutics Inc :FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy as treatment for acute radiation syndrome.  Full Article

Pluristem Therapeutics says phase III CLI trial cleared to commence enrollment in U.S. and EU
Monday, 13 Feb 2017 

Pluristem Therapeutics Inc : Company expects to begin enrolling patients in phase iii cli trial​ study in first half of 2017 . Pluristem reports second quarter fiscal 2017 highlights & provides calendar 2017 outlook . Study initiation of pivotal phase iii trial in cli received clearance from regulatory authorities in U.S., U.K. and Germany .Pivotal phase iii cli trial cleared to commence enrollment in U.S. and EU in h1 2017.  Full Article

Pluristem signs term sheet for $30 million equity investment agreement
Tuesday, 25 Oct 2016 

Pluristem Therapeutics Inc : Pluristem signs term sheet for $30 million equity investment agreement with a leading institutional life sciences fund . Pluristem therapeutics inc says funds to support late-stage pivotal trials for pluristem's cell therapies . Pluristem therapeutics inc - parties plan to enter into definitive agreements no later than december 26, 2016 . Pluristem therapeutics inc - shares will be sold at $1.77 . The shares will be subject to a lock up agreement for 6 months after closing of agreement . Parties plan to enter into definitive agreements no later than december 26, 2016 . Pluristem therapeutics - pluristem will issue to innovative medical approximately 4.4 million warrants to purchase shares of pluristem's common stock .Pluristem therapeutics-innovative medical will have one seat on co's board for as long as it holds at least 12.5% of co's issued and outstanding stock.  Full Article

Pluristem receives positive feedback from FDA, gears up for phase III trial of PLX-PAD in critical limb ischemia
Tuesday, 2 Aug 2016 

Pluristem Therapeutics Inc : Pluristem receives positive feedback from FDA and gears up for Phase III trial Of PLX-PAD in critical limb ischemia . Multinational study to be conducted in U.S. and Europe . Estimated trial enrollment of approximately 250 patients . Also moving CLI indication forward in Europe and Japan .Look forward to starting U.S. Phase III trial with our cell therapy for treatment of CLI by early 2017.  Full Article

Pluristem advances towards late-stage trial of PLX-PAD for recovery post hip surgery
Wednesday, 27 Jul 2016 

Pluristem: Pluristem advances towards multinational phase III trial of PLX-PAD to improve recovery following surgery for hip fracture . Has already submitted protocol to European medicines agency for a single pivotal study in this indication .Pluristem is planning to meet with FDA later this year to discuss phase iii protocol.  Full Article

Pluristem advances its U.S. FDA trial in hematologic indication
Monday, 11 Jul 2016 

Pluristem Therapeutics Inc : Pluristem advances its U.S. FDA trial in hematologic indication .Trial received clearance from U.S. Food and Drug Administration earlier this year and enrollment is planned to begin in coming months.  Full Article

N.Korea threats spur U.S. search for new radiation therapies

Jan 31 The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome.